Skip to content
    EDBI logo

    EDBI

    SingaporeFounded 1991
    edbi.comLinkedIn
    Biotech & Life SciencesHealthcareClimate & EnergyHardware & SemiconductorsMobility & TransportationEnterprise SoftwareData & Analytics

    EDBI is a Singapore-based global investor that is the investment arm of the Singapore Economic Development Board (EDB) and Enterprise Singapore. Founded in 1991, EDBI invests in high-growth global technology companies across sectors including ICT, biomedical sciences, smart & sustainable technology, and key industries, helping them scale in Singapore and across Asia.

    Deal activity decreased year-over-year (4 deals in the last 12 months vs 8 prior). Average disclosed round size is $99.4M (across 138 rounds with reported amounts).

    Find people at EDBI on Goldilocks AI

    Portfolio

    121

    Fund Size

    —

    Top Stage

    Series C

    Last 12 Mo

    4

    Team

    CK

    Charmaine KNG

    Partner

    CG

    Christine GIAM

    Partner

    JO

    Jolene OOI PhD

    Partner

    YC

    YEUNG Chia Li

    Senior Partner

    AK

    Andrew Krishna EKAPUTRA

    Senior Principal

    CF

    Crystalbel FOO

    Associate Principal

    HA

    Harold AU

    Senior Principal

    JF

    Jodie FOO

    Associate Principal

    JH

    Joy HO

    Associate Principal

    KT

    Kenneth TEO

    Senior Principal

    KN

    Kenny NG

    Associate Principal

    LR

    LIM Rong Yang

    Senior Principal

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    161 investments
    CompanyRoundAmountDate
    Lumilens logoLumilensSeed$700MAug 2026
    CesiumAstro logoCesiumAstroSeries C—Feb 2026
    Antheia logoAntheiaSeries C$24MJan 2026
    Lumilens logoLumilensSeries C$700MJan 2026
    d-Matrix logod-MatrixSeries C$275MNov 2025
    Debut Biotechnology logoDebut BiotechnologyUnknown$20MAug 2025
    Hydroleap logoHydroleapGrowth$4.8MJul 2025
    TTacta SystemsSeries A$64MJun 2025
    Allay Therapeutics logoAllay TherapeuticsSeries D$57.5MJun 2025
    Antheia logoAntheiaSeries C$56MJun 2025
    Addepar logoAddeparSeries G$230MMay 2025
    Nuevocor logoNuevocorSeries B$45MMay 2025
    Callio Therapeutics logoCallio TherapeuticsSeries A$187MMar 2025
    Hydroleap logoHydroleapUnknown$4.8MJan 2025
    Nuevocor logoNuevocorSeries B$45MJan 2025
    Allay logoAllaySeries D$57.5MJan 2025
    Riverlane logoRiverlaneSeries C$75MAug 2024
    Neko Health logoNeko HealthSeries D$41MJun 2024
    Eko Health logoEko HealthSeries C$41MJun 2024
    Eko Health logoEko HealthSeries D$41MJan 2024
    LLxaSeed$10MNov 2023
    Automera logoAutomeraSeries A$16MSep 2023
    AlphaSense logoAlphaSenseSeries E$150MSep 2023
    Cellares logoCellaresSeries C$255MAug 2023
    ENDOWUS HOLDINGS PTE. LTD. logoENDOWUS HOLDINGS PTE. LTD.Series B$35MAug 2023
    Page 1 of 7

    Top Co-Investors

    Temasek Holdings (Private) Limited14 shared
    Novo Holdings A/S9 shared
    ClavystBio9 shared
    Intel Capital8 shared
    DFJ Growth8 shared
    Bessemer Venture Partners7 shared
    Ally Bridge Group7 shared
    SEEDS Capital7 shared
    Polaris Partners7 shared
    Meritech Capital7 shared
    SoftBank Vision Fund6 shared
    Sequoia Capital6 shared
    Peak XV Partners6 shared
    New Enterprise Associates6 shared
    Hillhouse Investment6 shared
    Square Peg Capital6 shared
    Norwest Venture Partners6 shared
    The Goldman Sachs Group, Inc.5 shared
    GV5 shared
    Endeavor5 shared

    Last updated: 7 October 2026